Tel: 1-631-626-9181 (USA)    44-207-097-1828 (Europe)
  Email:

CBpromise   

Our promise to you:
Guaranteed product quality, expert customer support.

24x7 CUSTOMER SERVICE
CONTACT US TO ORDER

Oncolytic Virus Service

Frequently Asked Questions: Oncolytic Virus Service

1. What are the types of oncolytic viruses?

2. What are characteristic features of standard oncolytic virus?

3. Oncolytic virus immunotherapy uses a modified virus that can both cause tumor cells to self-destruct and activate a greater immune response. How does it work?

4. For which cancers is it currently being used or being studied?

5. Do you need biosafety approval to receive oncolytic viruses?

6. Can oncolytic viruses be administered to animals intravenously?

7. Do you offer custom generation of oncolytic viruses?


1. What are the types of oncolytic viruses?

Oncolytic viruses are mainly divided into four types according to their mechanisms of action, including intrinsically tumor selective viruses, promoter inserted viruses, virulent gene deleted viruses and pseudo typed viruses.

2. What are characteristic features of standard oncolytic virus?

The standard characters of oncolytic virus stated that

1) They only replicate within tumor with high multiplication rate, not on normal cells;

2) Less or no virulence and infectivity than their wild types;

3) Genetically stable so that mutations and recombination with other viruses are minimized for manufacturing and safety issues;

4) Can inactivate anytime with antiviral drugs or other mechanisms;

5) Considerable mass production can be possible with good manufacturing practices.

3. Oncolytic virus immunotherapy uses a modified virus which can both cause tumor cells to self-destruct and activate a greater immune response. How does it work?

1) Oncolytic viruses are viruses that directly kill cancer cells and can also activate cells of the immune system, such as T cells and dendritic cells, to target and eliminate cancer throughout the body.

2) Moreover, oncolytic viruses can be genetically modified to produce immune-stimulating chemicals, or to make them more specific for cancer cells.

3) Oncolytic virus immunotherapies are often combined with other types of cancer immunotherapies, such as therapeutic cancer vaccines and mAb therapy.

4. For which cancers is it currently being used or being studied?

Oncolytic virus immunotherapies are currently being studied in clinical trials for may cancers, including: Reolysin (prostate, ovarian, lung, colorectal and breast), CAVATAK (melanoma), CG0070 (bladder), JX-594 (ovarian), MV-NIS (multiple myeloma) and many more.

5. Do you need biosafety approval to receive oncolytic viruses?

Before we ship you oncolytic viruses, we do not require you to have received biosafety approval. Nevertheless, most institutes require that scientists and labs have biosafety registration and approval from the institutional biosafety review committee prior to using any recombinant viruses. Please consider all oncolytic viruses as a biohazard and take the necessary actions to ensure personnel and environment protection.

6. Can oncolytic viruses be administered to animals intravenously?

Our high-titer oncolytic viruses are suspended in biocompatible buffer and can be injected intravenously into animals. We propose that dilute the viruses to the desired dose level in sterile normal saline and keep them on ice until use. Our high purity and high titer viral stocks are prepared specially for in vivo antitumor efficacy experiments and are convenient for studies in mice.

7. Do you offer custom generation of oncolytic viruses?

Yes, we can provide customized, reliable and high-quality oncolytic virus therapy development services ranging from virus engineering, cell assays to animal testing.

Quick Inquiry

   Please input "biogene" as verification code.